Slide 1: Full Year 2025 Results
Full Year 2025 Results Thomas Meier, CEO Falk Neukirch, CFO March 26, 2026
Slide 2: Executive summary, Financial overview, Guidance 2026, Strategy, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2026, Strategy 4 Appendix 2
Slide 3: Executive Summary: My First Days in Office: Listen & Learn
Executive Summary My First 54 Days in Office: Listen & Learn Two virtual international First townhall meetings interview > 20 one-on-ones conducted, > 15 leadership & group with talents in more meetings scheduled person Met with Key Met with largest Medios shareholders in Partners & c. 30+ yrs in Ph
Slide 4: Highlights FY 2025
Executive Summary Highlights FY 2025 FY 2025: Overall, solid financials, mainly driven by 12-month consolidation of Ceban • Revenue up by 10.4% to €2.1bn Financials • Disproportionate EBITDA pre increase to €93.1m (+17.8%) leading to an EBITDA pre margin expansion of 4.5%; 2.7% organic EBITDA pre gr
Slide 5: QoQ – Revenue & EBITDApre
Executive Summary QoQ – Revenue & EBITDApre Revenue (€m) EBITDA pre¹ (€m) CAGR2 ~8.0% CAGR2 ~24.0% -c -c 538 549 507 24.6 24.0 490 493 23.2 23.1 23.3 483 485 22.7 431 422 441 456 451 17.2 16.1 15.0 15.1 14.1 14.3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023 2024 2025
Slide 6: ESG Highlights 2025
Executive summary ESG Highlights 2025 Sustainability Report in accordance with Corporate Sustainability Reporting Directive (CSRD) Proportion of women We are committed to the 65% UN Global Compact Corporate Responsibility in workforce 0.01% Initiative and its 43% Customer complaint principles in the
Slide 7: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2026, Strategy 4 Appendix 7
Slide 8: FY 2025 – Solid Group financials
Financial overview FY 2025 – Solid Group financials In € million FY 2025 FY 2024 ∆ in % Comments Revenue 2,078.7 1,883.0 10.4% Revenue growth of 10.4% mainly driven by strong organic growth of Gross profit1 203.7 154.6 31.6% PS, and first-time full-year consolidation of Ceban gross margin in % 9.8%
Slide 9: FY 2025 – Revenue Growth Mainly Driven By PS And IB
Financial overview FY 2025 – Revenue Growth Mainly Driven By PS And IB YoY Revenue in €m FY 24 Organic Inorganic FY 25 Comments Pharmaceutical Supply (PS) 1,580.0 108.8 1,688.8 • Inorganic growth attributable to Ceban (IB) Patient-Specific Therapies (PST) 213.6 6.5 220.1 • Organic growth mainly driv
Slide 10: FY 2025 – Strong EBITDA Pre Growth Mainly Due To IB
Financial overview FY 2025 – Strong EBITDA Pre Growth Mainly Due To IB YoY EBITDA pre1 in €m FY 24 Organic Inorganic FY 25 Comments Pharmaceutical Supply (PS) 50.0 2.5 52.5 • Organic growth of EBITDA pre by 2.7% driven by PS and IB Patient-Specific Therapies (PST) 23.3 -1.1 22.2 • Ceban (IB) contrib
Slide 11: FY 2025 – EBITDA Pre Posted Strong Disproportionate Growth
Financial overview FY 2025 – EBITDA Pre Posted Strong Disproportionate Growth Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million FY 25 FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 FY 24 FY 25 FY 24 Segment rev
Slide 12: Financing Structure
Financial overview Financing Structure • Syndicate loan concluded in Nov 2024 : €225m, consisting of • term loan of €125m, term: 5 yrs, annual redemption €25m; value as of 31 December 25: €100m and • Revolving credit facility (RCF) €100m, term 5 (+1 +1) yrs; drawn as of 31 December 25: €55m, potenti
Slide 13: Guidance 2026, Strategy
1 Executive Summary 2 Financial Overview 3 Guidance 2026, Strategy 4 Appendix “I am passionate about working for Medios because patient care is at the center of what we do.” 13
Slide 14: Guidance 2026
Guidance 2026 Guidance 2026 Revenue in €bn EBITDA pre1 in €m Comments • Revenue expected: €2.0 - €2.12bn (growth up to +2.0% compared to 2025) Up to +2.0% Up to +9.6% • EBITDA pre1 expected: €94 - 102m in 2026 (growth up to +9.6% compared to 2025) x ~2.00 - 93 94 - 102 2.08 2.12 4.5% 4.5% Up to 4.2%
Slide 15: Our Market System (1/2)
Strategy Our Market System (1/2) Mfg.* Commercial Wholesale Compounding Logistics Dispensing • Market access: • Operating • GMP/GDP-compliant • GMP/GDP- • Hospitals Pricing & warehouses/distribu patient-specific and compliant reimbursement tion centers stock/batch warehousing and • Physicians compou
Slide 16: Our Market System (2/2)
Strategy Our Market System (2/2) Mfg.* Commercial Wholesale Compounding Logistics Dispensing Pharmaceutical Supply (PS) Business Patient-Specific Therapies (PST) units International Business (IB) Commercialization services1 Incl. generalist wholesale Cold-chain only Pharmacies only2 Market ~ €10 – 1
Slide 17: We Secure Supply
Strategy We Secure Supply Extension of Pharmaceutical Supply business as pharmaceutical entrepreneur (Pharmazeutischer Unternehmer (PhU)) • Exclusive distribution for Germany and full regulatory management for established originator products (e. g. Novartis) 17
Slide 18: International Business – Medicine Shortages
Strategy International Business – Medicine Shortages Promethazine 25 mg tablets Shortage • Early 2025: risk of shortage identified by sole generic supplier • Market demand: >500,000 tablets/month • Confirmed supply depletion in Q3 2025 • Import exemptions insufficient to meet demand Development • Ea
Slide 19: Organizational Development – New CFO Stefan Bauerreis
Strategy Organizational Development – New CFO Stefan Bauerreis Profile “I am truly delighted to take on this new role and to embrace all the challenges ahead, contributing as a member of the Executive Board to shaping the future of Medios. I will, in my capacity as CFO, contribute with full commitme
Slide 20: Focus Activities 2026
Guidance 2026 Focus Activities 2026 One Team Medios • Harmonize business- & planning processes for compounding & pharmacy supply business • ERP/SAP(S4HANA) roll-out for Medios Pharma • Ensure better insights and teamwork resulting in faster decisions Operational excellence • Network optimization - b
Slide 21: Medios 2nd Capital Markets Day
Medios 2nd Capital Markets Day Date: 28-29 Sep 2026 Where: Breda, The Netherlands WELCOME AT Ceban in Breda 21
Slide 22: Question-and-answer session
Q&A Question-and-answer session: · If you have a question for our speakers, please dial: * 9 # on your telephone keypad now to enter the queue – Once your name has been announced, you can ask a question. · If you are logged in via the webcast tool, you can also submit questions at any time using the
Slide 23: Thank You!
THANK YOU!
Slide 24: Appendix
1 Executive Summary 2 Financial Overview 3 Guidance 2026, Strategy 4 Appendix “I work for Medios because I can contribute to patient care that meets the highest quality standards.” 24
Slide 25: Successful AGM: May 27, 2025 – Selected Agenda Items
Appendix Successful AGM: May 27, 2025 – Selected Agenda Items Approval of adjusted Compensation system for the Executive Board • Realignment of the Short-Term Incentive (STI) New financial KPI: Operational cash flow • Objective: stronger focus on operational performance indicators • Promotion of eff
Slide 26: ESG Highlights 2026 (March)
Appendix ESG Highlights 2026 (March) 0 63 100 Exceeds the industry benchmark D– C A+ Top 15% in the Industry CCC AA AAA Top 43% in the Industry 100 0 41 100 Top 13% in the Industry 100 15.4 0 Top 9% in the Industry (low risk) Source: Reports of respective organization 26
Slide 27: Successful Share Buyback Offer - July 2025
Appendix Successful Share Buyback Offer - July 2025 • Offer Share buyback: Up to 1,000,000 bearer shares of current share Capital: €25,505,723 (approx. 3.92% ) • Offer price per share: €12.50 (Approx. +9.3% premium over the 5-day XETRA average closing price) • Authorization: Granted by the AGM on Ju
Slide 28: Q4 2025 - Revenue Growth Mainly Driven By PS
Appendix Q4 2025 - Revenue Growth Mainly Driven By PS YoY Revenue in €m Q4 24 Organic Inorganic Q4 25 Comments Pharmaceutical Supply (PS) 388.8 60.6 449.3 Organic growth 14.1%: a result of strong PS revenue increase and also contribution Patient-Specific Therapies (PST) 52.1 2.0 54.1 of IB; PST cont
Slide 29: Q4 2025 - EBITDA Pre Slightly Below Q4 2024 Level
Appendix Q4 2025 - EBITDA Pre Slightly Below Q4 2024 Level YoY EBITDA pre1 in €m Q4 24 Organic Inorganic Q4 25 Comments Pharmaceutical Supply (PS) 13.0 0.8 13.8 • Organic growth by IB and PS • Decrease by PST Patient-Specific Therapies (PST) 6.5 -2.5 4.1 International Business (IB) 6.5 0.4 0.2 7.1 S
Slide 30: Key Figures (1/2)
Appendix Key Figures (1/2) in € thousand FY 2025 FY 2024 ∆ in % Q4 2025 Q4 2024 ∆ in % Revenue 2,078,652 1,883,038 10.4% 548,655 482,533 13.7% Pharmaceutical Supply 1,688,799 1,579,989 6.9% 449,323 388,765 15.6% Patient-Specific Therapies 220,133 213,642 3.0% 54,116 52,068 3.9% International 169,195
Slide 31: Key Figures (2/2)
Appendix Key Figures (2/2) in € thousand FY 2025 FY 2024 ∆ in % Q4 2025 Q4 2024 ∆ in % Earnings per share (in €) Undiluted 0.61 0.51 19.6% 0.19 0.08 >100.0% Diluted 0.61 0.51 19.6% 0.19 0.08 >100.0% Adjusted 2 1.94 1.61 20.5% 0.44 0.37 18.9% Investments (CAPEX) 8,291 6,308 31.4% 3,576 2,751 30.0% Ca
Slide 32: Q4 2025 – Financials
Appendix Q4 2025 – Financials Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million Q4 25 Q4 24 Q4 25 Q4 24 Q4 25 Q4 24 Q4 25 Q4 24 Q4 25 Q4 24 Q4 25 Q4 24 Segment revenue – extern. 449.3 388.8 54.1 52.1 45.0 41.5 0
Slide 33: The Medios share Shareholder Structure
Appendix The Medios share Shareholder Structure 65.2% Free float1 Basic Information • 6.4% Janus Henderson • 6.1% Axxion • 2.99% SEB Investment Share Capital €25,505,723 • 3.9% Treasury shares2 • 2.4% Paladin Asset Management No. of shares 25,505,723 Free float 19.7% Martin Hesse3 Share class No-par
Slide 34: Total Target Remuneration Remuneration System For The Executive Board
Appendix Remuneration System For The Total Target Remuneration Executive Board ESG Compensation structure of the total target remuneration Non-performance related fixed remuneration 28 – 35% Performance related remuneration 65 – 72% 1. Annual Short-Term-Incentive (STI) (target: 100%) 28 – 35%, STI t
Slide 35: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 Claudia.Nickolaus@medios.group 35
Slide 36: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 37: Full Year 2025 Results
Full Year 2025 Results Thomas Meier, CEO Falk Neukirch, CFO March 26, 2026